Article
Hematology
Mahasweta Gooptu, Rizwan Romee, Andrew St Martin, Mukta Arora, Monzr Al Malki, Joseph H. Antin, Christopher N. Bredeson, Claudio G. Brunstein, Saurabh Chhabra, Ephraim J. Fuchs, Nilanjan Ghosh, Michael R. Grunwald, Christopher G. Kanakry, Natasha Kekre, Jospeh P. McGuirk, Ian K. McNiece, Rohtesh S. Mehta, Marco Mielcarek, Fillipo Milano, Dipenkumar Modi, Ran Reshef, Scott R. Solomon, Mark A. Schroeder, Edmund K. Waller, Yoshiro Inamoto, Robert J. Soiffer, Mary Eapen
Summary: After comparing outcomes of 2036 haploidentical and 284 matched unrelated donor (MUD) transplantations with posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, it was found that MUD transplants had lower acute GVHD and nonrelapse mortality rates, as well as higher disease-free and overall survival, especially in recipients of reduced-intensity regimens. However, no significant differences were observed in patients receiving myeloablative conditioning regimens, highlighting the importance of donor-recipient HLA matching for allogeneic transplantation.
Article
Oncology
Amandine Le Bourgeois, Maxime Jullien, Alice Garnier, Pierre Peterlin, Marie C. Bene, Thierry Guillaume, Patrice Chevallier
Summary: This study aimed to assess the feasibility and safety of using PTCY as the sole prophylaxis for GVHD in adult patients. However, the study had to be stopped due to an unacceptable rate of severe acute GVHD. Despite this, overall survival and GVHD-free relapse-free survival remained good.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Jaroslaw Dybko, Malgorzata Sobczyk-Kruszelnicka, Sebastian Makuch, Siddarth Agrawal, Krzysztof Dudek, Sebatian Giebel, Lidia Gil
Summary: This study compared the outcomes of patients who received post-transplant cyclophosphamide (PTCy) or conventional immunosuppressants after allogeneic hematopoietic cell transplantation. The study found that patients receiving PTCy had lower rates of acute graft-versus-host disease and cytomegalovirus reactivation, and higher survival rates. Further research with a larger sample size is needed to confirm these results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Emanuele Angelucci, Boris Afanasyev, Jan J. Cornelissen, Simona Sica, Ellen Meijer, Fabio Ciceri, Gwendolyn Van Gorkom, Nicolaus Kroger, Hans Martin, Pietro Pioltelli, Antonio Risitano, Jonathan Canaani, Bipin N. Savani, Jaime Sanz, Mohamad Mohty
Summary: In the setting of PTCy for patients with acute leukemia, haplo bone marrow transplantation resulted in a lower incidence of GvHD compared with UD mobilized peripheral blood stem cell transplantation. However, differences in GvHD did not affect overall survival outcomes, suggesting both donor sources are equally acceptable for allo-HCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Immunology
Xiaodi Ma, Zhengli Xu, Tingting Han, Yuanyuan Zhang, Wei Han, Haixia Fu, Xiaohui Zhang, Fan Lin, Xiaojun Huang, Lanping Xu
Summary: This study modified the Beijing Protocol for haplo-HSCT in SAA patients, achieving successful and stable engraftment while reducing the incidence of severe acute GVHD. In the first batch of 17 patients who received the novel regimen, all patients achieved transplantation without primary graft failure, resulting in a 100% survival rate.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Shigeo Fuji, Junichi Sugita, Yuho Najima, Tatsuya Konishi, Takashi Tanaka, Hiroyuki Ohigashi, Tetsuya Eto, Koji Nagafuji, Nobuhiro Hiramoto, Ken-ichi Matsuoka, Yumiko Maruyama, Shuichi Ota, Jun Ishikawa, Toshiro Kawakita, Takashi Akasaka, Tomohiko Kamimura, Masayuki Hino, Takahiro Fukuda, Yoshiko Atsuta, Kimikazu Yakushijin
Summary: Reduced- and standard-dose PTCY were found to have comparable major clinical outcomes in patients undergoing haplo-HCT for haematological malignancies.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Rebeca Bailen, Maria Jesus Pascual-Cascon, Manuel Guerreiro, Lucia Lopez-Corral, Anabelle Chinea, Arancha Bermudez, Antonia Sampol, Inmaculada Heras, Estefania Garcia-Torres, Melissa Torres, Jose Rifon Roca, Beatriz Herruzo, Jaime Sanz, Marta Fonseca, Pilar Herrera, Mercedes Colorado, Leyre Bento, Oriana Lopez-Godino, Carmen Martin-Calvo, Paula Fernandez-Caldas, Maria Marcos-Jubilar, Isabel Sanchez-Ortega, Carlos Solano, Victor Noriega, Karem Humala, Gillen Oarbeascoa, Jose Luis Diez-Martin, Mi Kwon
Summary: This retrospective study compared the outcomes of haploidentical and HLA identical HSCT in AML patients using PTCY. The results showed no significant differences in survival outcomes and GVHD between the two groups. However, the incidence of acute GVHD was lower in the HLA identical group.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Immunology
Christo Tsilifis, Su Han Lum, Zohreh Nademi, Sophie Hambleton, Terence J. Flood, Eleri J. Williams, Stephen Owens, Mario Abinun, Andrew J. Cant, Mary A. Slatter, Andrew R. Gennery
Summary: Hematopoietic stem cell transplantation and gene therapy are the only curative therapies for severe combined immunodeficiency (SCID). This study found that TCR alpha beta-HaploSCT has comparable outcomes to matched unrelated donor transplants (MUD) and conditioning improves myeloid chimerism and immunoglobulin freedom in long-term survivors.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Hengwei Wu, Yeqian Zhao, Fei Gao, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Pengxu Qian, He Huang, Yanmin Zhao
Summary: A post-hoc analysis of a prospective clinical trial compared outcomes of haploidentical donor (HID) vs. matched sibling donor (MSD) peripheral blood stem cell transplants in patients with hematologic malignancies. The study found that overall survival, relapse-free survival, non-relapse mortality rate, and relapse incidence were similar between HID and MSD cohorts. Subgroup analysis suggested that patients with positive measurable residual disease in first complete remission may have better overall survival with an HID transplant. The study concluded that HID transplants can provide outcomes comparable to MSD transplants and should be recommended for patients with positive measurable residual disease in first complete remission.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Hematology
Javier Marco-Ayala, Jaime Sanz, Ines Gomez-Segui, Aitana Balaguer-Rosello, Juan Montoro, Manuel Guerreiro, Pedro Chorao, Ana Facal, Marta Villalba, Miguel Angel Sanz, Javier de la Rubia, Pilar Solves
Summary: Post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis increases the transfusion burden in HLA-matched related donor hematopoietic stem cell transplantation (HSCT), but is associated with a lower risk of acute and chronic GVHD and better survival outcomes compared to standard cyclosporine A-based prophylaxis.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Immunology
Maryam Barkhordar, Amir Kasaeian, Ghasem Janbabai, Hossein Kamranzadeh Fumani, Sahar Tavakoli, Amir Abbas Rashidi, Seied Asadollah Mousavi, Ardeshir Ghavamzadeh, Mohammad Vaezi
Summary: This study evaluated the long-term outcomes of haploidentical peripheral blood stem cell transplantation using the combination of anti-thymocyte globulin and post-transplant cyclophosphamide (ATG/PTCy). The results showed that the ATG/PTCy combination had a lower risk of graft-versus-host disease, but a higher risk of relapse compared to the standard ATG regimen. However, the combination had no significant effect on long-term outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Elisabetta Xue, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Teresa Clerici, Francesca Farina, Sara Mastaglio, Alessandro Bruno, Edoardo Campodonico, Rosamaria Nitti, Magda Marcatti, Andrea Assanelli, Consuelo Corti, Fabio Ciceri, Jacopo Peccatori, Raffaella Greco
Summary: The study investigated the impact of adding anti-T lymphocyte globulin to post-transplant cyclophosphamide in stem cell transplant patients, showing a significant reduction in the incidence of chronic GvHD. The addition of ATLG did not significantly affect acute GvHD but led to a lower incidence of chronic GvHD at one year. Survival outcomes were similar between the study group and control group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Immunology
Giuseppe Lia, Clara Di Vito, Stefania Bruno, Marta Tapparo, Lucia Brunello, Armando Santoro, Jacopo Mariotti, Stefania Bramanti, Elisa Zaghi, Michela Calvi, Lorenzo Comba, Martina Fasci, Luisa Giaccone, Giovanni Camussi, Eileen M. Boyle, Luca Castagna, Andrea Evangelista, Domenico Mavilio, Benedetto Bruno
Summary: Even with high-dose PT-Cy, acute and chronic GvHDs remain a clinical challenge. Reliable biomarkers for predicting their onset have yet to be identified. This study found a significant association between the expression profiles of EVs and their miRNA cargo with the onset of aGvHD. The correlation between EV expression profile and cargo with plasma biomarkers was also investigated.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Sarah Haebe, Alessia Fraccaroli, Elena Stauffer, Dusan Prevalsek, Anna K. Zoellner, Heidrun Drolle, Hans-Joachim Stemmler, Martin Dreyling, Michael von Bergwelt-Baildon, Johanna Tischer
Summary: Haplo-HSCT has emerged as a valuable alternative for patients without an available HLA-matched donor, with similar outcomes to MRD and URD transplantations. Haplo-HSCT also has a lower incidence of GvHD and better survival rates.
Article
Immunology
Paula Muniz, Cristina Andres-Zayas, Diego Carbonell, Maria Chicano, Rebeca Bailen, Gillen Oarbeascoa, Julia Suarez-Gonzalez, Ignacio Gomez Centurion, Nieves Dorado, David Gallardo, Javier Anguita, Mi Kwon, Jose L. Diez-Martin, Carolina Martinez-Laperche, Ismael Buno
Summary: In this study, polymorphisms of genes involved in the metabolism of cyclophosphamide were found to be associated with severe GVHD and toxicities in patients undergoing haploidentical HSCT. These findings have important implications for improving the clinical management of transplanted patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Eugenio Galli, Federica Sora, Stefan Hohaus, Alberto Fresa, Ilaria Pansini, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, Maria Assunta Limongiello, Sabrina Giammarco, Luca Laurenti, Andrea Bacigalupo, Patrizia Chiusolo, Valerio De Stefano, Simona Sica
Summary: mEASIX score can predict the occurrence of consumptive coagulopathy and CRS in patients receiving CAR-T cell therapy, and is associated with prognosis.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Elisabetta Metafuni, Antonella Cingolani, Massimo Fantoni, Patrizia Chiusolo, Sabrina Giammarco, Federica Sora, Eugenio Galli, Stefan Hohaus, Francesco D'Alo, Silvia Bellesi, Elena Maiolo, Eleonora Alma, Luca Laurenti, Idanna Innocenti, Francesco Autore, Maria Assunta Limongiello, Rosaria Santangelo, Simona Marchetti, Rosalba Ricci, Simona Sica
HEMATOLOGICAL ONCOLOGY
(2023)
Letter
Hematology
Filippo Frioni, Eugenio Galli, Federica Sora, Gina Zini, Simona Sica, Patrizia Chiusolo
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Review
Oncology
Wolfram C. M. Dempke, Maximilian Desole, Patrizia Chiusolo, Simona Sica, Martin Schmidt-Hieber
Summary: Acute myeloid leukaemias with MLL rearrangement are aggressive malignancies with poor prognosis. In MLL-rearranged leukaemias, menin functions as a co-factor and is essential for leukaemic transformation. Inhibition of menin can block leukaemogenesis and promote differentiation and apoptosis of leukaemic blasts. Several menin-MLL inhibitors are undergoing clinical evaluation for the treatment of acute leukaemias.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
Summary: The study validates the effectiveness of the Molecular International Prognostic Scoring System (IPSS-M) in predicting clinical outcomes of patients with myelodysplastic syndromes (MDS). IPSS-M improves the prognostic discrimination of the Revised International Prognostic Scoring System (IPSS-R) and enhances the accuracy of selecting candidates for hematopoietic stem cell transplantation (HSCT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stoelzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: A study on the association between the occurrence of GVHD and the relapse of AML in patients undergoing Haplo-HCT with PTCy-based GVHD prophylaxis found that while grade I acute GVHD was associated with better LFS, grade III-IV acute and extensive chronic GVHD were correlated with higher nonrelapse mortality and lower LFS.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Hematology
Nicola Piccirillo, Rossana Putzulu, Elisabetta Metafuni, Giuseppina Massini, Federica Fatone, Andrea Corbingi, Sabrina Giammarco, Maria Assunta Limongiello, Alessia Di Giovanni, Gina Zini, Andrea Bacigalupo, Luciana Teofili, Simona Sica, Patrizia Chiusolo
Summary: A study shows that early estimation of the success of peripheral blood stem cell collection can be achieved through genetic analysis and testing in donors, preventing risks and costs associated with suboptimal mobilization.
TRANSFUSION MEDICINE REVIEWS
(2023)
Editorial Material
Oncology
Patrizia Chiusolo, Fabio Ciceri, Simona Sica
FRONTIERS IN ONCOLOGY
(2023)
Letter
Biophysics
Eugenio Galli, Alice Di Rocco, Ilaria Pansini, Federico Frondizi, Martina Di Palma, Elisabetta Metafuni, Nicola Piccirillo, Maria Bianchi, Antonella Cingolani, Giovanni Fernando Torelli, Stefan Hohaus, Patrizia Chiusolo, Anna Paola Iori, Simona Sica, Maurizio Martelli, Federica Sora
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Eugenio Galli, Silvia Bellesi, Ilaria Pansini, Giacomo Di Cesare, Camilla Iacovelli, Rosalia Malafronte, Elena Maiolo, Patrizia Chiusolo, Simona Sica, Federica Sora, Stefan Hohaus
Summary: CD4+ and CD8+ chimeric antigen receptor T cells (CAR-T) play different roles in the in vivo anti-tumour response, and the CD4+/CD8+ ratio may impact CAR-T efficacy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Hematology
Eugenio Galli, Alberto Fresa, Silvia Bellesi, Elisabetta Metafuni, Elena Maiolo, Ilaria Pansini, Filippo Frioni, Francesco Autore, Maria Assunta Limongiello, Idanna Innocenti, Sabrina Giammarco, Patrizia Chiusolo, Gina Zini, Federica Sora
Summary: Impaired hematopoiesis after CAR-T treatment is common and can affect a wide range of patients, regardless of age and underlying disease. Trilinear cytopenias, hypogammaglobulinemia, B-cell aplasia, and T-cell impairment can negatively impact the infectious risk and quality of life of CAR-T recipients. This review provides an overview of hematopoietic defects after CAR-T, including definitions, pathogenesis, cytological aspects, risk of secondary myeloid malignancies, and the quantitative and functional impairment of T and B cells. Current recommendations and experiences regarding the management of cytopenias and defective B- and T-cell function are also discussed.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Cecilia Napodano, Gabriele Ciasca, Patrizia Chiusolo, Krizia Pocino, Laura Gragnani, Annunziata Stefanile, Francesca Gulli, Serena Lorini, Gessica Minnella, Federica Fosso, Riccardo Di Santo, Sabrina Romano, Valerio Basile, Valerio De Stefano, Gian Ludovico Rapaccini, Anna Linda Zignego, Enrico Di Stasio, Mariapaola Marino, Umberto Basile
Summary: Prolonged B cells stimulation by HCV can lead to autoimmunity characterized by elevated levels of cryoglobulins, rheumatoid factor, and free light chains of immunoglobulins. This study aimed to identify an immunological signature for early-stage vasculitis when cryoprecipitate is undetectable. The results showed that patients with supposed circulating cryoglobulins exhibited serological parameters similar to type II and III cryoglobulinemia. Analysis of clonal IgH and TCR rearrangements proved to be the best option for early diagnosis of extrahepatic complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Meeting Abstract
Hematology
Patrizia Chiusolo
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Eugenio Galli
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)